Faulkneraycock6870

Next, overexpression of HHIP resulted in significant (p<0.05) and time-dependent decrease in the growth of the HepG2 cells. The decrease in growth of the HepG2 cells was found to be mainly due to induction of apoptosis which was accompanied by increase in Bax and decrease in Bcl-2 expression. The wound healing assay showed that HHIP overexpression caused a remarkable decrease in the migration of the HepG2 cells. Furthermore, the transwell assay showed that the invasion of the HepG2 cells decreased by 65% upon HHIP overexpression.

Taken together, HHIP may serve as potential molecular marker and therapeutic target for liver cancer management.

Taken together, HHIP may serve as potential molecular marker and therapeutic target for liver cancer management.

To explore the association of the plasma transforming growth factor-β1 (TGF-β1) level and blood lymphocyte/monocyte ratio (LMR) with the pathological grade, clinical stage and prognosis of prostate cancer (PCa).

A total of 86 PCa patients treated in our hospital were enrolled. The changes in the expression of TGF-β1 were observed in patients with different clinical stages, different Gleason scores and different ages, and with or without bone metastasis. The correlation between blood LMR and clinicopathological features of PCa patients was detected. Moreover, the univariate and multivariate analyses were performed for clinicopathological factors and progression-free survival (PFS) after treatment, respectively.

In terms of the clinical stage II, III and IV, the number of patients with high TGF-β1 expression was significantly larger than that with low TGF-β1 expression (p<0.05). Among those with Gleason score of 2-4 points, 5-6 points and 7-10 points, the number of patients with high TGF-β1 expression he two groups (p<0.05). It was found in the multivariate analysis that TGF-β1, Gleason score, clinical stage and lymph node metastasis were influencing factors for PFS after treatment (p<0.05).

The TGF-β1 level is positively correlated with the severity, clinical stage and pathological grade of PCa. LMR is negatively correlated with the depth of tumor infiltration, stage and grade. Clinical stage, TGF-β1, lymph node metastasis and Gleason score are influencing factors for PFS of PCa patients after treatment.

The TGF-β1 level is positively correlated with the severity, clinical stage and pathological grade of PCa. LMR is negatively correlated with the depth of tumor infiltration, stage and grade. Clinical stage, TGF-β1, lymph node metastasis and Gleason score are influencing factors for PFS of PCa patients after treatment.

The current research was set with a goal to characterize the anticancer role of ovatodiolide against human prostate cancer along with the underlying mechanism of its action.

The proliferation of prostate cancer cells was assessed by using the CCK8 reagent. Seladelpar datasheet DAPI and acridine orange (AO)/ ethidium bromide (EB) staining procedures were employed for the analysis of cell apoptosis. Flow cytometric examination of prostate cancer cells was undertaken for the mitotic cell cycle analysis. The western blotting technique was used for the inference of expression levels of the proteins of interest.

In vitro administration of ovatodiolide led to decline of proliferation of prostate cancer cells. The reduction in proliferative rates was attributed to the induction of apoptosis of prostate cancer cells and mitotic cell cycle arrest. Furthermore, the anticancer effects of ovatodiolide on prostate cancer cells were exerted through the inhibition of Ras/Raf/MEK/ERK signaling cascade.

This study established the anticancer role of diterpenoid ovatodiolide in restricting the growth and proliferation of human prostate cancer cells.

This study established the anticancer role of diterpenoid ovatodiolide in restricting the growth and proliferation of human prostate cancer cells.

To explore the efficacy and safety of brachytherapy combined with endocrine therapy (ET) and external beam radiotherapy (EBRT) in the treatment of patients with intermediate- and high-risk localized prostate cancer (PCa).

A total of 128 patients with intermediate- and high-risk localized PCa treated in our hospital, were included, encompassing 64 cases undergoing brachytherapy combined with ET (control group), and 64 cases undergoing intensity-modulated EBRT on the above basis (combination group). The clinical efficacy, adverse reactions, the serum prostate specific antigen (PSA) level before and after treatment, maximum urinary flow rate (Qmax), and expanded prostate cancer index composite (EPIC) score were compared between the two groups. The overall survival (OS) of patients was analyzed using the Kaplan-Meier method and log-rank test.

After treatment, the EPIC scores of urinary function, intestinal function, sexual function and hormone function declined significantly in both groups, and they were siEBRT has definite efficacy in intermediate- and high-risk localized PCa, which can significantly improve the physiological function, raise the quality of life of patients, and effectively control the disease progression.

To identify new effective prognostic indicators for patients with nasopharyngeal carcinoma (NPC).

The immunohistochemical staining method was used to detect cyclooxygenase-2 (COX-2) protein in tumor tissues of 100 patients before and after chemoradiation. All the patients had stage III poorly differentiated NPC.

The positive expression of COX-2 was decreased before and after chemotherapy. The expression levels of COX-2 in patients before treatment was associated with T stage (p<0.05). The changes in the positive expression of COX-2 following treatment was also associated with T stage (p<0.05). The clinical response rate (CR+PR) exhibited significant differences (p<0.05) in patients with negative, weakly positive, partially positive, and strongly positive COX-2 expression before treatment. The clinical response rate (CR+PR) exhibited significant differences (p<0.05) compared with the patients who were negative or weakly positive. The COX-2 positive expression level of patients with NPC before treatment was closely associated with the survival time and survival rate of the patients (p<0.